TOP TEN perturbations for 39319_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39319_at
Selected probe(set): 205270_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39319_at (205270_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-4.147084
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

EBNA2 overexpr. study 1 (24h) / EBNA2 overexpr. study 1 (4h)

Relative Expression (log2-ratio):-3.8194027
Number of Samples:3 / 3
Experimental EBNA2 overexpr. study 1 (24h)
EREB2-5 cell line stably transfected with the chimeric Epstein-Barr virus-encoded nuclear antigen 2 (EBNA2) and control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene and . CAT was used as a negative control. Briefly, before the CAT and EBNA2 induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline and estrogen was added. Expression of EBNA2 was induced after addition of estrogen and expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 24 hours after induction. Because EBNA2 is essential for the proliferation of EBV-infected cells, EREB2-5 cells grow only in the presence of estrogen. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline.
Control EBNA2 overexpr. study 1 (4h)
EREB2-5 cell line stably transfected with the chimeric Epstein-Barr virus-encoded nuclear antigen 2 (EBNA2) and control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene and . CAT was used as a negative control. Briefly, before the CAT and EBNA2 induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline and estrogen was added. Expression of EBNA2 was induced after addition of estrogen and expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 4 hours after induction. Because EBNA2 is essential for the proliferation of EBV-infected cells, EREB2-5 cells grow only in the presence of estrogen. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline.

Crohn's disease study 10 / colorectal cancer study 13 (tvvad)

Relative Expression (log2-ratio):3.5764666
Number of Samples:4 / 3
Experimental Crohn's disease study 10
Colon biopsies derived from patients with Crohn's disease.
Control colorectal cancer study 13 (tvvad)
Colon biopsies derived from patients with low grade tubulovillous/villous adenoma.

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):3.4077091
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-3.3798323
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

collecting duct carcinoma study 1 / normal kidney tissue (fetal)

Relative Expression (log2-ratio):3.283742
Number of Samples:2 / 2
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue (fetal)
Normal fetal kidney tissue samples.

PMA study 3 (shRNA contr.) / mock treated / transduced Jurkat cell sample

Relative Expression (log2-ratio):3.2494907
Number of Samples:2 / 2
Experimental PMA study 3 (shRNA contr.)
Jurkat cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control mock treated / transduced Jurkat cell sample
Jurkat cells were transduced with a control shRNA and then mock treated.

renal cell carcinoma study 4 / normal kidney tissue (fetal)

Relative Expression (log2-ratio):3.2072172
Number of Samples:26 / 2
Experimental renal cell carcinoma study 4
Tumor tissue samples from the kidney of patients with renal cell carcinoma (RCC).
Control normal kidney tissue (fetal)
Normal fetal kidney tissue samples.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):3.129942
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-3.111578
Number of Samples:8 / 2
Experimental expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.